乌司他丁在脓毒症治疗中的研究进展
Research Progress of Ulinastatin in the Treatment of Sepsis
DOI: 10.12677/ACM.2023.1392077, PDF,   
作者: 邢家瑜, 于湘友*：新疆医科大学第一附属医院重症医学中心，新疆 乌鲁木齐
关键词: 乌司他丁；脓毒症；炎症反应；研究报告；Ulinastatin； Sepsis； Inflammatory Response； Research Report
摘要: 乌司他丁是从健康男性尿液中提取出来的一种广泛蛋白酶抑制剂，能够抑制多种蛋白酶的水解活性，虽然目前乌司他丁说明书中的主要临床适应症仍为用于急性胰腺炎、慢性复发性胰腺炎的急性恶化期和急性循环衰竭抢救的辅助用药，但随着对脓毒症全身炎症反应的进一步认识和对乌司他丁药理作用的深入研究，目前已有多项动物和临床研究表明乌司他丁对于脓毒症的治疗有一定的临床疗效，并且在近期的脓毒症相关诊疗与共识中也有所推荐使用。因此，本文将从乌司他丁的来源、药理作用以及对脓毒症治疗的机制和效果进行综述，以期为乌司他丁用于脓毒症的临床治疗和研究提供相关的证据和支持。
Abstract: Ulinastatin is a widespread protease inhibitor extracted from the urine of healthy males, capable of inhibiting the hydrolytic activity of a variety of proteases. Although the main clinical indications of Ulinastatin in the specification of the current ustatin are still for acute pancreatitis, acute exacerba-tion of chronic relapsing pancreatitis, and acute circulatory failure as an auxiliary drug, with the further recognition of systemic inflammatory response to sepsis and in-depth study of Ulinastatin pharmacology, there are now a number of animal and clinical studies have demonstrated that Uli-nastatin has a certain clinical efficacy for the treatment of sepsis, and has been recommended for use in the recent sepsis-related diagnosis and treatment and consensus. Therefore, in this review, we will summarize the source of Ulinastatin, its pharmacological effects, and the mechanisms and effects on sepsis treatment, with the aim of providing relevant evidence and support for the use of Ulinastatin in the clinical treatment and research of sepsis.
文章引用：邢家瑜, 于湘友. 乌司他丁在脓毒症治疗中的研究进展[J]. 临床医学进展, 2023, 13(9): 14844-14850. https://doi.org/10.12677/ACM.2023.1392077

参考文献

[1] Singer, M., Deutschman, C.S., Seymour, C.W., et al. (2016) The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA, 315, 801-810. [Google Scholar] [CrossRef] [PubMed]
[2] Rudd, K.E., Johnson, S.C., Agesa, K.M., et al. (2020) Global, Regional, and National Sepsis Incidence and Mortality, 1990-2017: Analysis for the Global Burden of Disease Study. The Lancet, 395, 200-211. [Google Scholar] [CrossRef] 
[3] Van der Poll, T., Shankar-Hari, M. and Wiersinga, W.J. (2021) The Immunology of Sepsis. Immunity, 54, 2450-2464. [Google Scholar] [CrossRef] [PubMed]
[4] 陶广华, 张随随, 朱玲钰, 等. 乌司他丁的药理作用机制及临床应用进展[J]. 中国药房, 2017, 28(35): 5020-5023.
[5] 毛刚, 吴清安, 刘磊. 乌司他丁的药理作用机制及临床应用进展[J]. 山东医药, 2015, 55(30): 94-96.
[6] Atal, S.S. and Atal, S. (2016) Ulinastatin—A Newer Potential Therapeutic Option for Multiple Organ Dysfunction Syndrome. Journal of Basic and Clinical Physiology and Pharma-cology, 27, 91-99. [Google Scholar] [CrossRef] [PubMed]
[7] 中国中西医结合学会急救医学专业委员会, 《中国中西医结合急救杂志》编辑委员会. 脓毒性休克中西医结合诊治专家共识[J]. 中华危重病急救医学, 2019, 31(11): 1317-1323.
[8] 王仲, 魏捷, 朱华栋, 等. 中国脓毒症早期预防与阻断急诊专家共识[J]. 中国急救医学, 2020, 40(7): 577-588.
[9] 朱晴, 张逸雪, 刘洋, 等. 脓毒症的病理生理机制研究进展[J]. 中华医院感染学杂志, 2022, 32(16): 2551-2555.
[10] Zhang, Q., Lenardo, M.J. and Baltimore, D. (2017) 30 Years of NF-κB: A Blossoming of Relevance to Human Pathobiology. Cell, 168, 37-57. [Google Scholar] [CrossRef] [PubMed]
[11] Luan, Y.Y., Jia, M., Zhang, H., et al. (2017) The Potential Mechanism of Extracellular High Mobility Group Box-1 Protein Mediated p53 Expression in Immune Dysfunction of T Lymphocytes. Oncotarget, 8, 112959-112971. [Google Scholar] [CrossRef] [PubMed]
[12] Karnad, D.R., Bhadade, R., Verma, P.K., et al. (2014) Intravenous Administration of Ulinastatin (Human Urinary Trypsin Inhibitor) in Severe Sepsis: A Multicenter Randomized Con-trolled Study. Intensive Care Medicine, 40, 830-838. [Google Scholar] [CrossRef] [PubMed]
[13] Xu, Q., Yan, Q. and Chen, S. (2018) Ulinastatin Is Effective in Reducing Mortality for Critically Ill Patients with Sepsis: A Causal Mediation Analysis. Scientific Reports, 8, Article No. 14360. [Google Scholar] [CrossRef] [PubMed]
[14] Li, S.T., Dai, Q., Zhang, S.X., et al. (2018) Ulinastatin Attenu-ates LPS-Induced Inflammation in Mouse Macrophage RAW264.7 Cells by Inhibiting the JNK/NF-κB Signaling Path-way and Activating the PI3K/Akt/Nrf2 Pathway. Acta Pharmacologica Sinica, 39, 1294-1304. [Google Scholar] [CrossRef] [PubMed]
[15] 章梦丽, 李文强. 脓毒症并发急性呼吸窘迫综合征的治疗策略[J]. 中国急救医学, 2017, 37(10): 883-888.
[16] Cao, C., Yin, C., Shou, S., et al. (2018) Ulinastatin Protects Against LPS-Induced Acute Lung Injury by Attenuating TLR4/NF-kappaB Pathway Activation and Reducing Inflammatory Me-diators. Shock, 50, 595-605. [Google Scholar] [CrossRef] 
[17] Song, Z., Chen, G., Lin, G., et al. (2013) The Ultra-Early Protective Effect of Ulinastatin on Rabbit Acute Lung Injury Induced by Paraquat. BMC Emergency Medicine, 13, S7. [Google Scholar] [CrossRef] 
[18] Fang, M., Zhong, W.H., Song, W.L., et al. (2018) Ulinastatin Ameliorates Pulmonary Capillary Endothelial Permeability Induced by Sepsis through Protection of Tight Junctions via Inhibition of TNF-α and Related Pathways. Frontiers in Pharmacology, 9, Article No. 823. [Google Scholar] [CrossRef] [PubMed]
[19] Xiao, S.H., Luo, L., Liu, X.H., et al. (2018) Curative Efficacy and Safety of Traditional Chinese Medicine Xuebijing Injections Combined with Ulinastatin for Treating Sepsis in the Chi-nese Population: A Meta-Analysis. Medicine (Baltimore), 97, e10971. [Google Scholar] [CrossRef] 
[20] 李乐辉, 杨远征, 林润, 等. 不同剂量血必净注射液联合乌司他丁注射液治疗脓毒症合并急性肺损伤的临床观察[J]. 中国药房, 2020, 31(13): 1617-1621.
[21] 何梅英, 陈文婷. 乌司他丁对脓毒症急性肺损伤的保护作用研究[J]. 临床急诊杂志, 2019, 20(3): 232-234.
[22] Bi, C.F., Liu, J., Yang, L.S., et al. (2022) Research Progress on the Mechanism of Sepsis Induced Myocardial Injury. Journal of In-flammation Research, 15, 4275-4290. [Google Scholar] [CrossRef] 
[23] Hunter, J.D. and Doddi, M. (2010) Sepsis and the Heart. British Journal of Anaesthesia, 104, 3-11. [Google Scholar] [CrossRef] [PubMed]
[24] Qiu, J., Xiao, X., Gao, X., et al. (2021) Ulinastatin Protects against Sep-sis-Induced Myocardial Injury by Inhibiting NLRP3 Inflammasome Activation. Molecular Medicine Reports, 24, Article No. 730. [Google Scholar] [CrossRef] [PubMed]
[25] Yu, Z., Rayile, A., Zhang, X., et al. (2017) Ulinastatin Protects against Lipopolysaccharide-Induced Cardiac Microvascular Endothelial Cell Dysfunction via Downregulation of lncRNA MALAT1 and EZH2 in Sepsis. International Journal of Molecular Medicine, 39, 1269-1276. [Google Scholar] [CrossRef] [PubMed]
[26] 张锦鑫, 沈括, 李俊杰, 等. 脓毒症相关性急性肝损伤的流行病学特点及致病因素分析[J]. 中华急诊医学杂志, 2022, 31(2): 203-209.
[27] Song, Y., Miao, S., Li, Y., et al. (2019) Ulinastatin Attenuates Liver Injury and Inflammation in a Cecal Ligation and Puncture Induced Sepsis Mouse Model. Journal of Cellular Biochemistry, 120, 417-424. [Google Scholar] [CrossRef] [PubMed]
[28] Peerapornratana, S., Manrique-Caballero, C.L., Gómez, H., et al. (2019) Acute Kidney Injury from Sepsis: Current Concepts, Epidemiology, Pathophysiology, Prevention and Treatment. Kidney International, 96, 1083-1099. [Google Scholar] [CrossRef] [PubMed]
[29] Zafrani, L., Payen, D., Azoulay, E., et al. (2015) The Microcircula-tion of the Septic Kidney. Seminars in Nephrology, 35, 75-84. [Google Scholar] [CrossRef] [PubMed]
[30] Matsuda, J., Namba, T., Takabatake, Y., et al. (2018) Anti-oxidant Role of Autophagy in Maintaining the Integrity of Glomerular Capillaries. Autophagy, 14, 53-65. [Google Scholar] [CrossRef] [PubMed]
[31] Li, T., Ji, X., Liu, J., et al. (2022) Ulinastatin Improves Renal Microcirculation by Protecting Endothelial Cells and Inhibiting Autophagy in a Septic Rat Model. Kidney and Blood Pressure Research, 47, 256-269. [Google Scholar] [CrossRef] [PubMed]
[32] Haussner, F., Chakraborty, S., Halbgebauer, R., et al. (2019) Challenge to the Intestinal Mucosa during Sepsis. Frontiers in Immunology, 10, Article No. 891. [Google Scholar] [CrossRef] [PubMed]
[33] 李祥, 杨春波, 古丽菲热∙塔依尔, 等. 乌司他丁通过抑制脓毒症大鼠肠道NLRP3炎症小体活化发挥肠道黏膜屏障的保护作用[J]. 中华危重病急救医学, 2021, 33(2): 192-197.
[34] 尹海燕, 陶珮, 叶小玲, 等. 乌司他丁对老年脓毒症患者肠屏障功能的保护[J]. 中华急诊医学杂志, 2016, 25(2): 177-181.
[35] Chen, L., Jin, S., Yang, M., et al. (2022) Integrated Single Cell and Bulk RNA-Seq Analysis Revealed Immunomodulatory Effects of Ulinastatin in Sepsis: A Multicenter Cohort Study. Frontiers in Im-munology, 13, Article ID: 882774. [Google Scholar] [CrossRef] [PubMed]
[36] Han, D., Shang, W., Wang, G., et al. (2015) Ulinastatin- and Thymosin α1-Based Immunomodulatory Strategy for Sepsis: A Meta-Analysis. International Immunopharmacology, 29, 377-382. [Google Scholar] [CrossRef] [PubMed]

为你推荐